The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
== Awards and honours == 2011 Royal Society of Edinburgh Young Academy of Scotland 2018 Wellcome Trust Prize for Outstanding Achievement in Public Engagement in the Biomedical Sciences 2018 "Super Zena" Award 2022 Royal Society of Edinburgh elected Fellow of the Royal Society of Edinburgh (FRSE)
== SC == sc – (s) Sardinian language (ISO 639-1 code) Sc – (s) Scandium SC (s) Cruiser Submarine (US Navy hull classification) c Saint Kitts and Nevis (FIPS 10-4 country code; from Saint Christopher) Seychelles (ISO 3166 digram) South Carolina (postal symbol) SCA (i) Service Contract Act Sexual Compulsives Anonymous Society for Creative Anachronism SCAP – (a) Supreme Commander Allied Powers (Allied occupation of Japan) sccm – (s) Standard cubic centimetre per minute (unit of measurement of fluid flow) sccs – (s) Standard cubic centimetre per second (unit of measurement of fluid flow) scfh – (s) Standard cubic foot per hour (unit of measurement of fluid flow) scfm – (s) Standard cubic foot per minute (unit of measurement of fluid flow) scfs – (s) Standard cubic foot per second (unit of measurement of fluid flow) SCG – (s) Serbia and Montenegro (ISO 3166 trigram; defunct since 2006) SCHIMS – (i) Soldier Combat Helmet Identification Marking System SCHIP – (a) State Children's Health Insurance Program (U.S.; often pronounced "ess-chip") SciFi – Science Fiction sCJD – (i) Sporadic Creutzfeldt–Jakob disease SCM – (i) Surface Contamination Module SCMODS – (s) State, County, Municipal Offender Data System SCN – (p) Suprachiasmatic Nucleus SCNT – (i) Somatic Cell Nuclear Transfer SCO (i) Santa Cruz Operation (initials later used by SCO Group) (s) Scotland (FIFA trigram; not eligible for an ISO 3166 or IOC trigram) (a) Shanghai Cooperation Organisation SCOTUS – (a) Supreme Court of the United States SCR – (s) Seychelles rupee (ISO 4217 currency code) SCRAM – (a) Safety Control Rod Axe Man SCS (i) Scan Correlated Shift Soil Conservation Service SCSI (a) Small Computer System Interface ("scuzzy") (i) Strategic and Combat Studies Institute SCT – (s) Scattered Sky (METAR Code) SCTP – (i) Stream Control Transmission Protocol Scuba – (a) Self Contained Underwater Breathing Apparatus SCUF – Slow Continuous Ultrafiltration SCUFN – (i) Sub-Committee on Undersea Feature Names (of GEBCO)
== Treatment == The primary treatment for urethral diverticulum is surgical. In women, the surgery is conducted transvaginally, usually when there is no acute inflammation to better aid dissection of the delicate tissues.
The lack of organization structure has led to project cancellations, as it can be difficult to convince other employees to work on them. In 2020, Valve acknowledged that this made it difficult to gather momentum and had slowed its output during the 2010s. Its VR projects and Half-Life: Alyx became a turning point, setting short-term studio-wide goals to focus the company. According to Walker, "We sort of had to collectively admit we were wrong on the premise that you will be happiest if you work on something you personally want to work on the most." In January 2023, People Make Games released a report on Valve's corporate structure and culture, based on interviews with several current and former employees. They found that Valve's flat structure and stack-ranking compensation system created a poor release record and a lack of employee diversity. In 2024, Forbes estimated that Newell owned 50.1% of Valve, with the rest owned by employees. As part of Wolfire Games' lawsuit over Steam policies, case documents revealed details related to Valve's employee structure. Valve had 60 employees in 2003 and had approximately 350 employees between 2012 and 2021. Employees are categorized into administration, game development, Steam development and (from 2011) hardware development.
Sources: en.wikipedia.org
Aerobic metabolism is up to 15 times more efficient than anaerobic metabolism (which yields 2 molecules of ATP per 1 molecule of glucose). However, some anaerobic organisms, such as methanogens are able to continue with anaerobic respiration, yielding more ATP by using inorganic molecules other than oxygen as final electron acceptors in the electron transport chain. They share the initial pathway of glycolysis but aerobic metabolism continues with the Krebs cycle and oxidative phosphorylation. The post-glycolytic reactions take place in the mitochondria in eukaryotic cells, and in the cytoplasm in prokaryotic cells. Although plants are net consumers of carbon dioxide and producers of oxygen via photosynthesis, plant respiration accounts for about half of the CO2 generated annually by terrestrial ecosystems.
=== Early life and education === Kimon Georgiev Stoyanov was born on 11 August 1882 in the town of Tatar Pazardzhik, then part of Eastern Rumelia, into a middle-class family. He was nicknamed "The Greek" because his mother was of Greek descent. His paternal grandfather, called Stoyan Balkachiyata, moved to the town from the village of Debrashtitsa in the early 19th century. His father was Georgi Stoyanov Krustyov, born around 1848. His maternal grandfather was Todor Bogdanov, who came to Pazardzhik from the village of Kalugerovo. His mother was Maria Bogdanova-Abadzhieva, born around 1858. He had an older brother and sister, so he was the youngest child in his family. At the time, his father died of tuberculosis only three months after his birth. He graduated primary education in Pazardzhik in 1897. He was firstly interested in engineering, but his family couldn't afford to study abroad, so they later directed him into starting his military career, where he was accepted into the Military University in Sofia.
== Uses == HaloTagged fusion proteins can be expressed using standard recombinant protein expression techniques. Furthermore, there are several commercial vectors available that just require insertion of a gene of interest. Since bacterial dehalogenases are relatively small and the reactions described above are foreign to mammalian cells, there is no interference by endogenous mammalian metabolic reactions. Once the fusion protein has been expressed, there is a wide range of potential areas of experimentation including enzymatic assays, cellular imaging, protein arrays, determination of sub-cellular localization, and many additional possibilities. Recently, HaloTag has been engineered to create hybrid protein + small molecule biosensors of neuronal activity. These sensors undergo a conformational change in response to calcium concentration spikes during neuronal firing; this conformational change modulates the conformation of a HaloTag-bound dye molecule.
Sources: en.wikipedia.org
=== Severe combined immunodeficiency === Severe combined immunodeficiency (SCID) caused by T-cell deficiency is a disorder that was recently added to newborn screening programs in some regions of the United States. Wisconsin was the first state to add SCID to their mandatory screening panel in 2008, and it was recommended for inclusion in all states' panels in 2010. Since December 2018 all US states perform SCID screening. As the first country in Europe, Norway started nationwide SCID screening January 2018. Identification of infants with SCID is done by detecting T-cell receptor excision circles (TRECs) using real-time polymerase chain reaction (qPCR). TRECs are decreased in infants affected with SCID. SCID has not been added to newborn screening in a wide scale for several reasons. It requires technology that is not currently used in most newborn screening labs, as PCR is not used for any other assays included in screening programs. Follow-up and treatment of affected infants also requires skilled immunologists, which may not be available in all regions. Treatment for SCID is a stem cell transplant, which cannot be done in all centers.
Of his character, he said: "Originally, I was married. I had this kid and I did this research and I didn't know that what I was researching had this effect. And someone got killed and I had these regrets and I'm trying to stop what I'm doing, but they can't let me so they're chasing me. And then all of a sudden I turn into this 24-year-old machinist and I turned to (director) Andrew Davis and I said, 'What happened to the movie I said yes to? What happened to that script? Where did that go?' And he said, 'No, I got something better,' and so I just had to go with it."
=== Other research === As of July 2013, afamelanotide was in phase II and III clinical trials for vitiligo and other skin diseases. A medication for rheumatoid arthritis, tofacitinib, has been tested for the treatment of vitiligo. According to a 2021 review, JAK inhibitors like ruxolitinib show promise in targeting the IFN-γ-chemokine signaling axis implicated in vitiligo pathogenesis and improving NSV. In mid-2026, pharmaceutical corporation Pfizer announced positive phase III trial results of ritlecitinib, a kinas-inhibiting drug, to treat NSV. Additionally, a 2026 study published in The Lancet showed positive results with the JAK inhibitor upadacitinib. As of 2024, mitochondrial antioxidants, NRF2 inhibitors, and TBK1 inhibitors were emerging as potential therapeutic options to block the effects of melanocytic mtDNA release associated with vitiligo. The head of a 2025 Osaka Metropolitan University research team suggested that its discoveries, which included the presence of dormant pigment cells in vitiligo patches, could lead to new treatment approaches.
== Safety and potential drug interactions == L-arginine is recognized as safe (GRAS-status) at intakes of up to 20 grams per day. L-arginine is found in many foods, such as fish, poultry, and dairy products, and is used as a dietary supplement. It may interact with various prescription drugs and herbal supplements.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。